VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer
PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment
298
Participants
Timeline
Start Date
July 1, 2024
Primary Completion Date
November 1, 2026
Study Completion Date
December 1, 2026
Conditions
CancerCancer Metastatic
Interventions
BIOLOGICAL
Vedolizumab
300 mg IV at weeks 0, 3, 6, 14, and 22
BIOLOGICAL
Placebo
300 mg IV at weeks 0, 3, 6, 14, and 22
All Listed Sponsors
lead
University of Calgary
OTHER
NCT06337695 - VERIFY: Vedolizumab for the Prevention of Immune Checkpoint Inhibitor Related Diarrhea or Colitis in Patients With Cancer | Biotech Hunter | Biotech Hunter